Javier Reque

Dr. Javier Reque

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2016 in American Journal of Nephrology
Verified
Journal Article
Open access
PDF file
JRJavier Reque
Javier Reque
AGAna Garcia-Prieto
Ana Garcia-Prieto
TLTania Linares
Tania Linares
AVAlmudena Vega
Almudena Vega
SASoraya Abad
Soraya Abad
JLJuan Manuel López-Gómez
Juan Manuel López-Gómez
Background: We evaluated the prevalence, determinants and prognosis value of pulmonary hypertension (PH) in non-dialysis chronic kidney disease (CKD) patients. Methods: This is a prospective study with stages 3-5 non-dialysis-dependent CKD patients. PH was estimated by Doppler echocardiography and defined as a pulmonary artery systolic pressure above 35 mm Hg. Results: Three hundred fifty-three patients were recruited, of whom 94 (26.6%) had PH. Prevalence of PH increased with the decline of renal function: 21.6, 24.1, and 31.7% in stages 3, 4, and 5, respectively. Independent predictors of PH were age, estimated glomerular filtration rate (eGFR), history of cardiovascular (CV) events, the presence of an arteriovenous fistulae (AVF), and left ventricular (systolic and diastolic) dysfunction. Over a median follow-up of 22 months, 71 patients died (20%). After multivariate adjustment for age, gender, previous CV disease, diastolic and systolic dysfunction, PH remained as an independent predictor of all-cause mortality (hazards ratio [HR] 1.84, 95% CI 1.06-3.18, p = 0.02). One hundred patients (28%) had a new onset CV event. After adjustment for age, gender, previous CV disease, systolic and diastolic dysfunction, PH maintains its independent association with CV events (HR 2.77, 95% CI 2.00-3.25, p < 0.001). Conclusions: PH prevalence rises as kidney function declines. Main determinants of PH are age, eGFR, previous CV disease, the presence of an AVF and left ventricular systolic or diastolic dysfunction. PH is an independent predictor of all-cause mortality and CV events.

12 October 2018 in Blood Purification
Verified
Journal Article
Closed access
PDF file
JRJavier Reque
Javier Reque
AAAlejandro Pérez Alba
Alejandro Pérez Alba
NPNayara Panizo
Nayara Panizo
JSJuan José Sánchez-Canel
Juan José Sánchez-Canel
MPMaria Jose Pascual
Maria Jose Pascual
RPRamón Pons Prades
Ramón Pons Prades
Background: Recent evidence suggests a better reduction rate of some uremic toxins with expanded hemodialysis (HDx). Methods: Prospective study including 8 hemodialysis patients. We divided the study in 2 phases; within the first one, we assigned 4 patients (group 1) to undergo online hemodiafiltration with a PF 210H dialyzer, and the other 4 patients (group 2) to undergo HDx with the high retention onset Theranova 500 dialyzer during 24 sessions. Later, during the second phase and after a washout period, the same patients were switched to receive HDx (group 1) and HDF (group 2). Results: No differences were found in the Urea and β2-microglobulin reduction ratio. However, in the case of myoglobin, the reduction ratio with HDF was 35 vs. 60% with HDx (p < 0.001). Similarly, in the case of prolactin, the reduction ratio with HDF was 45 and 61% with HDx (p < 0.001). Conclusions: We conclude that HDx is not inferior to online hemodiafiltration in the clearance of small and middle molecules and could be superior in the clearance of larger middle molecules.

30 March 2016 in Nephrology
Verified
Journal Article
Closed access
PDF file
JRJavier Reque
Javier Reque
BQBorja Quiroga
Borja Quiroga
CRCaridad Ruiz
Caridad Ruiz
MVMaria Teresa Villaverde
Maria Teresa Villaverde
AVAlmudena Vega
Almudena Vega
JLJ. Manuel López‐Gómez
J. Manuel López‐Gómez

20 February 2023 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
AGAna García-Prieto
Ana García-Prieto
JFJosé Carlos de la Flor
José Carlos de la Flor
ECElisabet Coll
Elisabet Coll
EIElena Iglesias
Elena Iglesias
JRJavier Reque
Javier Reque
FVFrancisco Valga
Francisco Valga
In recent years there has been an increasing interest in expanded hemodialysis (HDx), an emerging renal replacement therapy based on the use of medium cut-off membranes (MCO). Thanks to the internal architecture of these types of membranes, with a higher pore size and smaller fiber inner diameter to favor internal filtration rate, they can increase the removal of larger middle molecules in conventional hemodialysis. Secondarily, several reports suggest that this therapy potentially improve the outcomes for end-stage renal disease patients. However, HDx has not been defined yet and the characteristics of MCO membranes are not well stablished. The aim of this narrative review is to define HDx and summarize the dialyzers that have been used so far to perform this therapy, collect the evidence available on its efficacy and clinical outcomes compared with other hemodialysis techniques and settle the bases for its optimal prescription.

9 July 2019 in Kidney Diseases
Verified
Journal Article
Open access
PDF file
NGNayara Panizo Gonzalez
Nayara Panizo Gonzalez
JRJavier Reque
Javier Reque
BFBarbara Hernando Fuster
Barbara Hernando Fuster
ECEladio Collado-Boira
Eladio Collado-Boira
IMIgnacio Martinez-Navarro
Ignacio Martinez-Navarro
CDCarlos Hernando Domingo
Carlos Hernando Domingo
Purpose: We evaluated the incidence of acute kidney injury in a cohort of marathon participants. Methods: We conducted a prospective observational study focused on evaluating the incidence of kidney damage after a marathon, and its evolution in the first 48 h after the marathon in 88 runners who completed the Valencia Marathon. Results: From the 88 participants, 42 (48.28%) presented with acute kidney injury, mainly grade 1 (95.20%). Microscopic haematuria was observed in 29 runners (33%). Levels of interleukin 6, leukocytes, and neutrophils were markedly increased at the marathon’s finish line. Conclusions: Our results confirmed that there are slight transient changes in glomerular filtration rate and inflammatory activation after a marathon.

17 May 2022 in Journal of Thyroid Research
Verified
Journal Article
Open access
PDF file
JRJavier Reque
Javier Reque
BPBeatriz Garcia Peris
Beatriz Garcia Peris
NGNayara Panizo Gonzalez
Nayara Panizo Gonzalez
AAAlejandro Perez Alba
Alejandro Perez Alba
Luis D'MarcoLuis D'Marco
Luis D'Marco
ECEladio Collado-Boira
Eladio Collado-Boira
Introduction. Renal function and thyroid metabolism are tightly related. However, evidence about subclinical hypothyroidism prevalence in patients with chronic kidney disease and its related factors is scarce. Objectives. Our aim is to analyze subclinical hypothyroidism prevalence and its related factors in patients with advanced chronic kidney disease. Materials and methods. Nondialysis-dependent patients with chronic kidney disease at stages 3 to 5 were included. Other inclusion criteria were age above 18 years and clinical stability. Patients with diagnosed thyroid illnesses were excluded. Subclinical hypothyroidism was defined as thyroid stimulating hormone (TSH) > 5.3 mU/L, with free thyroxine 4 (FT4) between 0.54 and 1.24 ng/dl. Filiation data, comorbidities, and routine blood and urine test results were registered. Results. A total of 299 patients were included. Of them, 184 (61.5%) were men. The mean age was 71 +/- 13 years old. The mean glomerular filtration rate (CKD-EPI) was 22 +/- 9 ml/min/1.73 m(2). According to chronic kidney disease stages, global distribution of patients was as follows: Stage 3, 67 patients (22.4%); Stage 4, 155 patients (51.8%); and Stage 5, 77 patients (25.8%). We found subclinical hypothyroidism in 54 (18.1%) patients. According to chronic kidney disease stages, distribution of affected patients was as follows: Stage 3, 9 patients (13%); Stage 4, 25 patients (16.1%); and Stage 5, 20 patients (26%). Differences among stages were statistically significant. By univariate analysis, factors related with subclinical hypothyroidism were as follows: age RR 1.048 (95% CI 1.019-1.078; p=0.001), hypertension RR 2.705 (95% CI 1.026-7.130; p=0.04), glomerular filtration rate RR 0.962 (95% CI 0.929-0.996; p=0.03), and proteinuria higher than 1 gram/day RR 2.387 (95% CI 1.303-4.374; p=0.005). By multivariate analysis adjusted by age, hypertension, glomerular filtration rate, proteinuria, diabetes, and cardiovascular disease history, only age RR 1.016 (95% CI 1.009-1.028; p=0.04) and glomerular filtration rate RR 0.963 (95% CI 0.930-0.997; p=0.03) preserved their independent association with subclinical hypothyroidism. Conclusions. Subclinical hypothyroidism prevalence in patients with chronic kidney disease is high and increases with renal disease severity. Factors independently related to subclinical hypothyroidism are age and glomerular filtration rate.